454O A phase (Ph) I/II trial of the CXCR2 antagonist AZD5069 in combination with enzalutamide (ENZA) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) (2022)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.annonc.2022.07.583
Publication URI: http://dx.doi.org/10.1016/j.annonc.2022.07.583
Type: Journal Article/Review
Parent Publication: Annals of Oncology